This is a preview of subscription content, log in via an institution to check access.
Reference
Arbel R, et al. Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology : 23 Jan 2019. Available from: URL: http://doi.org/10.1016/j.amjcard.2019.01.021
Rights and permissions
About this article
Cite this article
Ezetimibe cost saving for prevention of CV events in T2DM. PharmacoEcon Outcomes News 822, 9 (2019). https://doi.org/10.1007/s40274-019-5661-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5661-8